Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)

first analysis on survival

For The J-Pops Investigators

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions. Methods: Between July 2005 and June 2007, 2316 clinically localized patients underwent permanent seed implantation. The primary endpoint was bRFS. One of the secondary endpoints was overall survival (OS). Results: The median age was 69 and performance status was 0 in 99.1% of participants. The median biologically effective dose (BED) was about 180 Gy 2 . During a median follow-up of 60.0 months, 8.4 and 5.9% had PSA failure by the Phoenix and the J-POPS definitions, respectively. The 5-year bRFSs based on the Phoenix and the J-POPS definitions were 89.1 and 91.6%, respectively. The 5-year OS was 97.3%. According to multivariate analyses, only age affected bRFS based on the Phoenix definition, whereas the risk group and BED independently affected bRFS based on the J-POPS definition. A spontaneous PSA decrease was seen in 91.1% of participants after PSA failure based on the Phoenix definition alone, but in only 22.2% after PSA failure based on the J-POPS definition alone. Conclusion: The world’s largest registration study, J-POPS, consisted of patients with longevity, and a highly quality-controlled BED resulted in excellent bRFS and OS. The high likelihood of PSA bounce by the Phoenix definition should be taken into account, especially in younger patients. Clinical trial information: NCT00534196.

元の言語英語
ページ(範囲)1148-1159
ページ数12
ジャーナルInternational Journal of Clinical Oncology
23
発行部数6
DOI
出版物ステータス出版済み - 12 1 2018

Fingerprint

Survival Analysis
Iodine
Prostatic Neoplasms
Seeds
Outcome Assessment (Health Care)
Prostate-Specific Antigen
Survival
Recurrence
Multivariate Analysis
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

これを引用

Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) : first analysis on survival. / For The J-Pops Investigators.

:: International Journal of Clinical Oncology, 巻 23, 番号 6, 01.12.2018, p. 1148-1159.

研究成果: ジャーナルへの寄稿記事

@article{e36e684292264caab989bce465ce7bf8,
title = "Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival",
abstract = "Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions. Methods: Between July 2005 and June 2007, 2316 clinically localized patients underwent permanent seed implantation. The primary endpoint was bRFS. One of the secondary endpoints was overall survival (OS). Results: The median age was 69 and performance status was 0 in 99.1{\%} of participants. The median biologically effective dose (BED) was about 180 Gy 2 . During a median follow-up of 60.0 months, 8.4 and 5.9{\%} had PSA failure by the Phoenix and the J-POPS definitions, respectively. The 5-year bRFSs based on the Phoenix and the J-POPS definitions were 89.1 and 91.6{\%}, respectively. The 5-year OS was 97.3{\%}. According to multivariate analyses, only age affected bRFS based on the Phoenix definition, whereas the risk group and BED independently affected bRFS based on the J-POPS definition. A spontaneous PSA decrease was seen in 91.1{\%} of participants after PSA failure based on the Phoenix definition alone, but in only 22.2{\%} after PSA failure based on the J-POPS definition alone. Conclusion: The world’s largest registration study, J-POPS, consisted of patients with longevity, and a highly quality-controlled BED resulted in excellent bRFS and OS. The high likelihood of PSA bounce by the Phoenix definition should be taken into account, especially in younger patients. Clinical trial information: NCT00534196.",
author = "{For The J-Pops Investigators} and Kazuto Ito and Shiro Saito and Atsunori Yorozu and Shinsuke Kojima and Takashi Kikuchi and Satoshi Higashide and Manabu Aoki and Hirofumi Koga and Takefumi Satoh and Toshio Ohashi and Katsumasa Nakamura and Norihisa Katayama and Nobumichi Tanaka and Masahiro Nakano and Naoyuki Shigematsu and Takushi Dokiya and Masanori Fukushima and Yutaka Takahashi and Iwao Tsukiyama and Yasutomo Nasu and Masaoki Harada and Takashi Fukagai and Takashi Yamashita and Akio Matsubara and Mikio Igawa and Shin Egawa and Yoshiyuki Kakehi and Youji Katsuoka and Hiroshi Kanetake and Yoshinobu Kubota and Hiromi Kumon and Ichiro Yamasaki and Kazuhiro Suzuki and Takashi Deguchi and Munehisa Ueno and Seiji Naito and Mikio Namiki and Shiro Baba and Kazushige Hayakawa and Yoshihiko Hirao and Tomoaki Fujioka and Shigeo Horie and Tsuneharu Miki and Masaru Murai and Hideki Yoshida and Jun Itami and Toshihiko Inoue and Katsunori Tatsugami and Junichi Inokuchi and Tomonari Sasaki",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s10147-018-1309-0",
language = "English",
volume = "23",
pages = "1148--1159",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)

T2 - first analysis on survival

AU - For The J-Pops Investigators

AU - Ito, Kazuto

AU - Saito, Shiro

AU - Yorozu, Atsunori

AU - Kojima, Shinsuke

AU - Kikuchi, Takashi

AU - Higashide, Satoshi

AU - Aoki, Manabu

AU - Koga, Hirofumi

AU - Satoh, Takefumi

AU - Ohashi, Toshio

AU - Nakamura, Katsumasa

AU - Katayama, Norihisa

AU - Tanaka, Nobumichi

AU - Nakano, Masahiro

AU - Shigematsu, Naoyuki

AU - Dokiya, Takushi

AU - Fukushima, Masanori

AU - Takahashi, Yutaka

AU - Tsukiyama, Iwao

AU - Nasu, Yasutomo

AU - Harada, Masaoki

AU - Fukagai, Takashi

AU - Yamashita, Takashi

AU - Matsubara, Akio

AU - Igawa, Mikio

AU - Egawa, Shin

AU - Kakehi, Yoshiyuki

AU - Katsuoka, Youji

AU - Kanetake, Hiroshi

AU - Kubota, Yoshinobu

AU - Kumon, Hiromi

AU - Yamasaki, Ichiro

AU - Suzuki, Kazuhiro

AU - Deguchi, Takashi

AU - Ueno, Munehisa

AU - Naito, Seiji

AU - Namiki, Mikio

AU - Baba, Shiro

AU - Hayakawa, Kazushige

AU - Hirao, Yoshihiko

AU - Fujioka, Tomoaki

AU - Horie, Shigeo

AU - Miki, Tsuneharu

AU - Murai, Masaru

AU - Yoshida, Hideki

AU - Itami, Jun

AU - Inoue, Toshihiko

AU - Tatsugami, Katsunori

AU - Inokuchi, Junichi

AU - Sasaki, Tomonari

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions. Methods: Between July 2005 and June 2007, 2316 clinically localized patients underwent permanent seed implantation. The primary endpoint was bRFS. One of the secondary endpoints was overall survival (OS). Results: The median age was 69 and performance status was 0 in 99.1% of participants. The median biologically effective dose (BED) was about 180 Gy 2 . During a median follow-up of 60.0 months, 8.4 and 5.9% had PSA failure by the Phoenix and the J-POPS definitions, respectively. The 5-year bRFSs based on the Phoenix and the J-POPS definitions were 89.1 and 91.6%, respectively. The 5-year OS was 97.3%. According to multivariate analyses, only age affected bRFS based on the Phoenix definition, whereas the risk group and BED independently affected bRFS based on the J-POPS definition. A spontaneous PSA decrease was seen in 91.1% of participants after PSA failure based on the Phoenix definition alone, but in only 22.2% after PSA failure based on the J-POPS definition alone. Conclusion: The world’s largest registration study, J-POPS, consisted of patients with longevity, and a highly quality-controlled BED resulted in excellent bRFS and OS. The high likelihood of PSA bounce by the Phoenix definition should be taken into account, especially in younger patients. Clinical trial information: NCT00534196.

AB - Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions. Methods: Between July 2005 and June 2007, 2316 clinically localized patients underwent permanent seed implantation. The primary endpoint was bRFS. One of the secondary endpoints was overall survival (OS). Results: The median age was 69 and performance status was 0 in 99.1% of participants. The median biologically effective dose (BED) was about 180 Gy 2 . During a median follow-up of 60.0 months, 8.4 and 5.9% had PSA failure by the Phoenix and the J-POPS definitions, respectively. The 5-year bRFSs based on the Phoenix and the J-POPS definitions were 89.1 and 91.6%, respectively. The 5-year OS was 97.3%. According to multivariate analyses, only age affected bRFS based on the Phoenix definition, whereas the risk group and BED independently affected bRFS based on the J-POPS definition. A spontaneous PSA decrease was seen in 91.1% of participants after PSA failure based on the Phoenix definition alone, but in only 22.2% after PSA failure based on the J-POPS definition alone. Conclusion: The world’s largest registration study, J-POPS, consisted of patients with longevity, and a highly quality-controlled BED resulted in excellent bRFS and OS. The high likelihood of PSA bounce by the Phoenix definition should be taken into account, especially in younger patients. Clinical trial information: NCT00534196.

UR - http://www.scopus.com/inward/record.url?scp=85048863471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048863471&partnerID=8YFLogxK

U2 - 10.1007/s10147-018-1309-0

DO - 10.1007/s10147-018-1309-0

M3 - Article

VL - 23

SP - 1148

EP - 1159

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 6

ER -